Objectives: To study effectiveness and predictors of tele-monitoring on metabolic outcome of T1DM CGM treated children in real world.

Methods: CGM data of 47 T1DM patients (3-18 years) were studied during two years (October 2016 - September 2018): 6 months without bi-weekly tele-consultations (T0), 6 months with connected CGM and tele-consultations (T1-2), 6 months washout period and 6 months without tele-consultations (T3). HbA1C, time-in-hypo, and days-in-hospital were measured. Relationship between metabolic outcome and age, gender, baseline HbA1C, insulin regimen (pen vs. pump), puberty and compliance towards the tele-consultations, was studied.

Results: 2.836.322 CGM values (16.479 total days) were analysed. Baseline HbA1C (±SD) for the total group was 7.7±1% and did not change significantly; time-in-hypo decreased from 8±5% (T0) to 5±3% (T2) (p=0.002) and increased to 6±4% (T3) (p=0.143). HbA1C of patients with HbA1C > 7.5% at T0 decreased significantly from 8.3±0.6% to 8±0.7% at T1 (p=0.024), to 8.1±1% at T2 (p=0.176) and stabilized at 8.1±1 at T3 (p=0.742). During 6 months of tele-monitoring, 352 therapy adjustments were proposed during 585 tele-consultations. In compliant patients (n=8) with baseline HbA1C >7.5%, HbA1C changed from 8.1±0.5% (T0) to 7.6±0.4% (T1) (p=0.029), to 7.3±0.3% (T2) (p=0.001), and to 7.9±0.9% at T3 (p=0.035) while time in hypo was on average 6% and 7% before and after the tele-consultations and 4% during tele-consultations. Time-in-range with this group improved by 6% during 6 months of tele-consultations, and number of serious hypos decreased from 9 (T0) to 1 (T2) and 1 (T3); days-in-hospital from 7 (T0) to 0 (T2). No effect of age, gender, insulin regimen or puberty was found on HbA1C or time-in-hypo.

Conclusions: A benefit of tele-consultations in pediatric CGM patients was seen only in compliant patients with HbA1C > 7.5%. Targeted use of tele-consultations can increase CGM benefits.


I. Gies: None. B. Vermeulen: None.


Belgian National Institute for Health and Disability Insurance

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.